Tag Archives: rare diseases

Orphan Drug Market to Reach $176 Billion by 2020, Says Report

By 2020, orphan drugs are expected to account for 19 percent of the total share of prescription drug sales excluding generics, reaching $176 billion in annual sales, according to EvaluatePharma’s Orphan Drug Report 2014. At 11 percent, this growth is set to be more than double the 5 percent growth rate of the overall prescription market, […]
Posted in Global, Orphan Drugs | Also tagged , , | Leave a comment

Swedish Firm Honored for Rare Disease Treatments

Swedish Orphan Biovitrum AB (Sobi) was last night presented with a EURORDIS Award for its commercial and development portfolio in the field of rare diseases. The award also recognized the company’s track record on access to drugs and its collaboration with patient organizations. EURORDIS is Europe’s largest patient organization in rare diseases. Its CEO, Yann […]
Posted in Europe, Events, Global, Orphan Drugs | Also tagged , , | Leave a comment

Europe: Expectations High for Rare Disease Day

Next week Europe will celebrate Rare Disease Day. This is an interesting example – one might almost say a rare example – of a successful attempt by a European interest group to capture public attention. It is now an annual awareness-raising event co-ordinated by the European rare diseases lobby group, EURORDIS. For this year’s celebration, […]
Posted in Europe, Events, Global, Guest Blog, Orphan Drugs | Also tagged , , , | Leave a comment

UK Plan for Rare Diseases: Little Focus on Access to Medicines

By Leela Barham. The European Commission mandated that all member states have a plan for rare diseases back in June 2009. With the EC deadline just weeks away, the UK has now finalized its own. But for those who were hoping it would have a clear focus on access to medicines, there’s little to be […]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , , | Leave a comment

Reflections on Rare Disease Day

The rare disease advocacy community convened yesterday for its annual Rare Disease Day celebration, marking another year of advances in the fight against ailments once almost entirely ignored by big Pharma. The fact that hundreds of rare diseases are finally attracting real attention from major researchers, not to mention big dollars, is attributable not only […]
Posted in Europe, FDA, Market Access, Orphan Drugs, Patient Communication, Regulatory | Also tagged | 1 Comment
  • Categories

  • Meta